Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Bill received his graduate training in immunology at UCSF and has held research director positions in biotech and pharma companies. His primary focus has been the invention, development, and use of new technology for antibody discovery. In 2008 Bill co-founded Crystal Bioscience and became its CSO with the goal of creating the most diverse and effective antibody repertoires possible from wild-type and transgenic animal systems. Ligand acquired Crystal Biosciences in October 2017.
OmniAb: Validated Therapeutic Antibody Discovery Platforms from Three Species
The OmniAb® portfolio of transgenic animals includes OmniRat®, OmniMouse® and OmniChicken™ for discovery of fully human HxL antibodies, and OmniFlic® for bispecific antibodies. Multiple OmniAb species provide diverse antibody repertoires and a variety of options regarding the antibody discovery process. OmniAb antibodies show high affinity and specificity, and excellent developabilty profiles. Five partner programs are in clinical development.
